Conghua Xie
Eli Lilly (United States)(US)Xuzhou Medical College(CN)Wenzhou Medical University(CN)Wuhan University(CN)Huaian First People’s Hospital(CN)Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University(CN)First Affiliated Hospital of Guangzhou University of Chinese Medicine(CN)Wuhan Institute of Virology(CN)Zhongnan Hospital of Wuhan University(CN)Second People’s Hospital of Huai’an(CN)Second Hospital of Tianjin Medical University(CN)Hubei Cancer Hospital(CN)Wuhan Center for Disease Control and Prevention(CN)Tianjin Medical University(CN)Nanjing Medical University(CN)Guangzhou Medical University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, RNA modifications and cancer
Most-Cited Works
- → SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China(2020)1,075 cited
- → A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group(2020)716 cited
- → Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial(2022)545 cited
- → Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial(2016)520 cited
- → Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)(2020)381 cited